Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 27 October 2023, 21:00 HKT/SGT
Share:
    

Source: LINLINE MEDICAL SYSTEMS
Groundbreaking Study Reveals the Effectiveness of New RecoSMA Laser Treatment for Diabetic Foot
A recent study published in the Journal of Wound Care (UK) has shed light on a revolutionary approach to diabetic foot care that promises hope and relief for millions worldwide.

LONDON, Oct 27, 2023 - (ACN Newswire) - LINLINE MEDICAL SYSTEMS, based in Riga, Latvia, has demonstrated the remarkable effectiveness of its distinctive RecoSMA laser technology in treating chronic wounds. The recent study, "Spatially modulated erbium YAG laser as a treatment for diabetic ulcer", published in the Journal of Wound Care (UK), was conducted using a MULTILINE laser system produced by the company.  

RecoSMA for Chronic Ulcers - Chronic ulcers treatment: a two-step approach
RecoSMA for Chronic Ulcers - Chronic ulcers treatment: a two-step approach

The study, conducted by a team of esteemed researchers, aimed to address the pressing issue of diabetic foot complications, which affect a substantial portion of the global population. According to the International Diabetes Federation, an alarming 463 million people are currently diagnosed with diabetes, projected to surge by 50% within the next three decades.

Diabetic foot ulcers are one of the most debilitating consequences of diabetes, often leading to severe complications, including amputations and significant financial burdens on patients and healthcare systems.

The dire reality is that individuals with diabetes face a 15-fold higher likelihood of undergoing lower extremity amputations than those without diabetes. Statistics indicate that, globally, a major amputation (above or below the knee) is performed on a person with diabetes every 20-30 seconds.

In this landmark study, researchers explored the use of a novel laser treatment for diabetic foot ulcers designed to revolutionize how we approach this chronic problem. By employing the spatially modulated high-power Erbium YAG (Er-YAG) laser technology, the team aimed to tackle diabetic foot ulcers in a two-step process that involved laser wound debridement and deep tissue biostimulation using the RecoSMA technology (implemented in "MULTILINE" laser system, produced by LINLINE MS).

The study included 59 patients with hard-to-heal diabetic foot ulcers and documented remarkable results.

The mean wound surface area at baseline was 25.7 cm2. The average number of laser treatment sessions required was 4.41, ranging from 1-11. The ulcers gradually reduced in size with each session, ultimately leading to complete wound closure in 100% of cases.

Laser treatment made it possible to clear wounds of necrotic tissue and microbial bioburden without damaging viable tissue. The procedures were painless on an outpatient basis.

The RecoSMA laser operates by activating the body's innate healing processes, fostering neovascularization, and expediting tissue regeneration. This mechanism facilitates wound healing through re-epithelialization originating from the wound's edges and granulation emerging from the wound bed's depths, all without the formation of fibrosis. This unique approach promotes scar-free and unimpeded wound healing, a pivotal factor in effective rehabilitation.

The impact of this research is profound. It suggests a potential paradigm shift in the way we approach diabetic foot ulcers, offering a beacon of hope for those affected by this debilitating condition. By harnessing the power of innovative laser therapy, we have the opportunity to enhance the quality of life for individuals suffering from diabetic foot complications and to reduce the economic strain on healthcare systems.

For more details about the technology, please visit the website:

https://www.non-healing-wound.care/

The link to the study: https://doi.org/10.12968/jowc.2023.32.Sup10a.S21

About us: LINLINE Medical Systems SIA (Riga, Latvia) is a world-leading company specialising in developing and manufacturing advanced medical lasers designed to treat various conditions in surgery, endoscopy, dermatology, gynaecology, wound healing and aesthetic medicine.

Company's website: https://linline-ms.com/.

Contact Information
Alex Troshkin, Co-founder, board member, at@linline-ms.com, +37122453227

Related Files
chilgar-andurkar-2023-spatially-modulated-erbium-yag-laser-as-a-treatment-for-diabetic-ulcer (1).pdf




Topic: Press release summary
Source: LINLINE MEDICAL SYSTEMS


http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Four major tech fairs open in October  
Oct 3, 2024 22:09 HKT/SGT
AVIA Announces "Vietnam in View" Conference, Highlighting Growth and Opportunities in Vietnam's Media and Entertainment Industry  
Oct 3, 2024 19:30 HKT/SGT
ALUXE Unveils Enchanting New Winnie the Pooh Wedding Ring Collection  
Oct 3, 2024 17:00 HKT/SGT
Toyota to Invest $500 Million in Joby Aviation  
Thursday, October 3, 2024 2:59:00 PM
CisgenX Awarded Smart Approved WaterMark Certification for Innovative Irrigation Solutions  
Oct 3, 2024 14:47 HKT/SGT
Spa IZUMI Launches "YON-KA Phyto Sleep Ritual"  
Oct 3, 2024 12:00 HKT/SGT
ADvance Pilipinas: "The Future of Advertising: Convergence and Divergence"  
Oct 3, 2024 11:08 HKT/SGT
Fujitsu and Supermicro announce strategic collaboration to develop green AI computing technology and liquid-cooled datacenter solutions  
Thursday, October 3, 2024 8:38:00 AM
Insightful Discussions on eMobility Await: Join Influential Speakers at London EV Show 2024  
Oct 2, 2024 18:36 HKT/SGT
Wadaoki Forest at the Mihara Machinery Works Certified as 'Nationally Certified Sustainably Managed Natural Site' by Ministry of the Environment  
Oct 2, 2024 14:42 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: